Laurus Labs Q1 FY26: CDMO Dreams, API Screams, and a P/E That Needs Counseling
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
Laurus Labs is back with a bang: ₹1,570 Cr in revenue (up 31% YoY) and ₹389 Cr in EBITDA (up 127%). But don’t pop the champagne just yet — the stock still trades at a P/E of 89. That’s not a multiple, that’s a cry for help.
2. Introduction with Hook
Imagine a chemistry nerd hitting the gym, bulking up on steroids (pharma ones), and suddenly becoming a contract manufacturing bodybuilder. That’s Laurus Labs for you. From generic APIs to CDMO glory, this stock is doing a pharma backflip in mid-air.
Two stats to make your eyebrows do the worm:
127% YoY EBITDA growth in Q1 FY26
₹5,929 Cr TTM revenue (despite ARV segment shrinkage)
3. Business Model – WTF Do They Even Do?
Basically, Laurus makes boring yet essential chemicals that keep global pharma ticking — APIs for anti-retrovirals, oncology, and other alphabet-soup diseases. But here’s the twist: they’ve gone all-in on CDMO, aka the SaaS of the pharma world — recurring, scalable, and much fancier sounding.
Their business segments:
Generic APIs (46% of revs) – falling, but stable
CDMO/CMO – the new obsession
Formulations – steady but not sexy
Synthesis & Biotech – slow cookers with long-term upside
In short: Pharma meets startup meets manufacturing sweatshop.
